FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 328:1715-1717 June 10, 1993 Number 23 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited

To the Editor: The article by Janssen et al. (Aug. 13 issue)¹ and the letter by Lurie et al. (Dec. 17 issue)² raise important issues with regard to the effectiveness of widespread screening for the human immunodeficiency virus (HIV) in acute care hospitals in the United States. These issues are also relevant in less industrialized nations. More than 10 million of the approximately 12 million cases of HIV infection in the world occur overseas; almost 8 million of these are in sub-Saharan Africa alone³. Different conclusions may be drawn when one considers the application of testing policies abroad.

Screening . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Hara, M. R., Thomas, B., Cascio, M. B., Bae, B.-I., Hester, L. D., Dawson, V. L., Dawson, T. M., Sawa, A., Snyder, S. H. (2006). Neuroprotection by pharmacologic blockade of the GAPDH death cascade. Proc. Natl. Acad. Sci. USA 103: 3887-3889 [Abstract] [Full Text]